Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

for
Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer,
Location: Huntersville NC, Detroit MI, Houston TX,
Sponsor: Qurgen Inc.

Sex: All

Age: 18+

Code: NCT05989724

Phase 1, Recruiting

AOH1996 for the Treatment of Refractory Solid Tumors

for
Refractory Malignant Solid Neoplasm, Osteosarcoma,
Location: Duarte CA, Long Beach CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT05227326

Phase 1, Recruiting

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

for
Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma,
Location: New York NY, Philadelphia PA, Duarte CA
Sponsor: BioInvent International AB

Sex: All

Age: 18+

Code: NCT04752826

Phase 1, Phase 2, Recruiting

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

for
Advanced Solid Tumor, Unresectable Solid Tumor,
Location: New York NY, Hackensack NJ, Philadelphia PA,
Sponsor: Clasp Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06778863

Phase 1, Recruiting

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

for
Advanced Cancer, Metastatic Cancer, Ovarian Cancer,
Location: Boston MA, Lake Success NY, New York NY,
Sponsor: Artios Pharma Ltd

Sex: All

Age: 18+

Code: NCT04657068

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study

for
Cancer, Tyrosine Kinase Mutation, Breast Cancer, Melanoma,
Location: Edmonton
Sponsor: University of Alberta

Sex: All

Age: 18 - 70+

Code: NCT05645510

Recruiting

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

for
Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer,
Location: Long Island City NY, Manhattan NY, Fairfax VA,
Sponsor: Accent Therapeutics

Sex: All

Age: 18+

Code: NCT06799065

Phase 1, Phase 2, Recruiting

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

for
Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer,
Location: Baltimore MD, Nashville TN, Houston TX, Los Angeles CA
Sponsor: AtlasMedx, Incorporated

Sex: All

Age: 18+

Code: NCT04503265

Phase 1, Phase 2, Recruiting

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

for
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma,
Location: Seattle WA
Sponsor: University of Washington

Sex: All

Age: 0+

Code: NCT06295965

Recruiting

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

for
Ovarian Cancer, Breast Cancer, Endometrial Cancer,
Location: Boston MA, New York NY, Philadelphia PA,
Sponsor: LigaChem Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT06774963

Phase 1, Recruiting

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

for
Endometrial Cancer, Cervical Cancer,
Location: Westbury NY, Howard Beach NY, Richmond VA, Miami FL,
Sponsor: Mayo Clinic

Sex: Female

Age: 18+

Code: NCT05051722

Recruiting

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

for
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma,
Location: Jacksonville FL, Grand Forks ND
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT05969860

Phase 2, Recruiting

Comprehensive Outcomes for After Cancer Health

for
Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer,
Location: Boston MA, Houston TX
Sponsor: Pack Health

Sex: All

Age: 18+

Code: NCT05349227

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

for
Advanced Solid Tumors, Non-Small Cell Lung Cancer,
Location: Huntersville NC, Grand Rapids MI, Irving TX
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07807956

Phase 1, Recruiting

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

for
Ovarian Cancer, Advanced Malignant Solid Tumor
Location: Chicago IL
Sponsor: University of Chicago

Sex: All

Age: 18+

Code: NCT07389239

Phase 1, Phase 2, Recruiting

INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study

for
Breast Cancer, Corpus Uteri Cancer, Ovary Cancer,
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham

Sex: All

Age: 18+

Code: NCT07671937

Recruiting

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

for
Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma,
Location: Jacksonville FL
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT07285044

Phase 2, Recruiting

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

for
Solid Tumor, Small Cell Lung Cancer (SCLC),
Location: Fort Worth TX, West Valley City UT, Los Angeles CA
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT07517198

Phase 1, Recruiting

Distance-Based Exercise to Preserve Function and Prevent Disability

for
Localized Malignant Solid Neoplasm, Anal Cancer,
Location: Boston MA, Mechanicsville VA, Richmond VA,
Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT07059884

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

for
Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer,
Location: Providence RI, Teaneck NJ, Syracuse NY, Fairfax VA,
Sponsor: AbbVie

Sex: Female

Age: 18+

Code: NCT07024784

Phase 2, Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial